Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01461993 · ClinicalTrials.gov registry record · Phase 2
A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 2,499
- Enrollment target
NCT01461993: Completed Phase 2 study, sponsored by Pfizer.
NCT01461993 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 2,499 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (1779% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01461993, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2,499 participants
- Enrollment target
Study Summary
This is a clinical study to assess the safety, tolerance and immunogenic response to Gardasil (human papilloma virus (HPV)) and rLP2086 vaccine. Healthy male and female subjects will be randomized into 1 of 3 groups; the trial will be an observer-blinded study to the injection being given; and, vaccinated with either Gardasil and rLP2086 concomitantly, rLP2086 and saline concomitantly, or Gardasil and saline concomitantly. The subjects are adolescent children between the ages of 11 and 17 years old.
Interventions
- BIOLOGICAL Gardasil
- BIOLOGICAL rLP2086 and Gardasil
- BIOLOGICAL rLP2086
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,499 participants |
| Start Date | 2011-09-28 |
| Est. Completion | 2013-07-06 |
| Phase | Phase 2 |
What the finished NCT01461993 record still lists
NCT01461993 is an interventional study that assigns participants to a tested intervention. Its 2,499 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (1779% higher).
The record links to 0 conditions, and to 3 interventions - of which Gardasil is the first listed.
NCT01461993 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01461993 about?
NCT01461993 is a clinical study titled "A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17". This is a clinical study to assess the safety, tolerance and immunogenic response to Gardasil (human papilloma virus (HPV)) and rLP2086 vaccine. Healthy male and female subjects will be randomized into 1 of 3 groups; the trial will be an observer-blinded study to the injection being given; and, vacc...
What is the current status of trial NCT01461993?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 2,499 participants. The study started on 2011-09-28. Estimated completion is 2013-07-06.
What interventions are being tested in trial NCT01461993?
The interventions under investigation include: Gardasil (BIOLOGICAL), rLP2086 and Gardasil (BIOLOGICAL), rLP2086 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01461993?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01461993's enrollment target sits among peer trials
2,499 8th of 2000 higher than 1,993 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001160 · 2,500 participants
Studies on Tumors of the Thyroid
- NCT01904188 · 2,500 participants
Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?
- NCT02257229 · 2,500 participants
Prospective Evaluation of Treatment for Clubfoot
- NCT02530658 · 2,500 participants
Next Generation Sequencing of Normal Tissues Prospectively in Pediatric Oncology Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI